Method Development and Validation for the Determination of Pravastatin in Human Plasma by Lc-Ms/MsLian Chen*, Paresh Joshi, Andrii Piatkivskyi, Kalem Aguilar and Jenny Lin
CMIC, Inc. 2860 Forbs Avenue, Hoffman Estates, IL 60192, USA
- *Corresponding Author:
- Lian Chen
CMIC, Inc. 2860 Forbs Avenue, Hoffman Estates
IL 60192, USA
E-mail: [email protected]
Received date: May 22, 2017; Accepted date: June 08, 2017; Published date: June 16, 2017
Citation: Chen L, Joshi P, Piatkivskyi A, Aguilar K, Lin J (2017) Method Development and Validation for the Determination of Pravastatin in Human Plasma by Lc-Ms/Ms. J Bioanal Biomed 9:137-143. doi: 10.4172/1948-593X.1000168
Copyright: © 2017 Chen L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A simple, rapid, sensitive and selective liquid chromatography/tandem mass spectrometry (LC/MS/MS) method was developed and validated for the quantification of pravastatin in human plasma. Pravastatin-D3 was used as an internal standard. The analyte was extracted from human plasma samples by liquid-liquid extraction technique. Due to the presence of isobaric metabolites, 3α-iso-pravastatin and 6-epi-pravastatin, chromatographic conditions were optimized, with a C18 column by using a mixture of 0.1% acetic acid in water and acetonitrile/methanol (43:57, v/v) as the mobile phase at a flow rate of 0.6 mL/min. The calibration curve obtained was linear (r2 ≥ 0.9900) over the concentration range of 0.500-500 ng/mL. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. The method was suitable for supporting clinical studies.